Table 1 Demographic characteristics of patients who received MMF treatment for six months or longer

Number of Patients

n = 86

Current age, median (range), y

53 (15–84)

Female sex, No. (%)

77 (90%)

NMO diagnosis, No. (%)

64 (74%)

NMOSD diagnosis, No. (%)

22 (26%)

Aquaporin-4 antibody positivity, No. (%)

74 (86%)

Age at onset, median (range), y

43 (6–68)

Overall disease duration, median (range), mo

71 (7–535)

Disease duration before receiving MMF, median (range), mo

71 (6–444)

Attack number before receiving MMF, median (range)

5 (1–33)

Duration of MMF treatment, median (range), mo

20 (6–89)

Abnormal autoantibodies^a, n (%)

39 (45%)

Coexisting with systemic autoimmune diseases

29 (34%)

Concurrent use of prednisone, n (%)

65 (76%)

treatment-naïve patients, n (%)

21 (24%)

 Corticosteroids^b, n (%)

33 (38%)

 Azathioprine, n (%)

15 (17%)

 Cyclophosphamide, n (%)

4 (5%)

 Rituximab, n (%)

2 (2%)

 Tacrolimus (FK506)

1 (1%)

 Methotrexate

1 (1%)

 β-interferons, n (%)

6 (7%)

 hydroxychloroquine sulfate, n (%)

2 (2%)

 Mitoxantrones, n (%)

1 (1%)